GRANTS / FUNDING
Funding for Phase 1 & 2
Annamycin has received over $2 million in grants (through its development partner) and has had $20 million in development dollars invested in furthering the technology and and is expected to receive an additional $2 to $3 million in the next 24 months for Phase I and Phase II clinical trials.
Annamycin has obtained an Orphan Drug designation in the US, which provides seven years of marketing exclusivity. Repeat of prior results should afford Annamycin an accelerated approval pathway as a 2nd line induction therapy for R/R AML.
DRUG DISCOVERY & DEVELOPMENT
Leading cancer research center in the world, drug discovery.
Moleculin Biotech, Inc.
Phase 1 and Phase 2
Annamycin is repeating a Phase I/II clinical trials, both in US and EU. The US trial (MB-104) has begun treating patients; the EU trial (MB-105) is about to begin. We believe a repeat of prior results should afford Annamycin an accelerated approval pathway as a 2nd line induction therapy for relapsed or refractory AML (R/R AML).
Acute Myeloid Leukemia
Other indications include sarcomas, Lewis Lung carcinoma and squamous cell carcinoma, among others.